المصدر: A Phase 1, Open-Label, Randomized, Single Dose Study to Evaluate the Effect of Injection Site on the Pharmacokinetics of Astegolimab in Healthy Subjects

المصدر: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

المصدر: A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

المصدر: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

المصدر: A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

المصدر: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma
Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, Theess W, Yang X, Staton TL, Choy DF, Fong A, Dash A, Dolton M, Pappu R, Brightling CE. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. doi: 10.1016/j.jaci.2021.03.044. Epub 2021 Apr 16.

المؤلفون: Kotani, Naoki, Dolton, Michael, Svensson, Robin J., Ribbing, Jakob, Friberg, Lena E., Vadhavkar, Shweta, Cheung, Dorothy, Staton, Tracy, Sperinde, Gizette, Jin, Jin, Putnam, Wendy S., Quartino, Angelica

المصدر: Journal of clinical pharmacology. 62(7):905-917

مصطلحات موضوعية: astegolimab, asthma, exposure-response, IL-33, population pharmacokinetics, ST2

وصف الملف: electronic

URL الوصول: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485053
https://doi.org/10.1002/jcph.2021
https://uu.diva-portal.org/smash/get/diva2:1696977/FULLTEXT01.pdf

المؤلفون: Glenfield Hospital, Leicester, Genentech, Inc.

المصدر: A Randomised Placebo-controlled Trial of Anti-ST2 in COPD (COPD-ST2OP)
Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, Haldar K, Wright A, Novotny P, Parker S, Glover S, Finch J, Quann N, Brookes CL, Hobson R, Ibrahim W, Russell RJ, John C, Grimbaldeston MA, Choy DF, Cheung D, Steiner M, Greening NJ, Brightling CE. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022 May;10(5):469-477. doi: 10.1016/S2213-2600(21)00556-7. Epub 2022 Mar 24.

المؤلفون: Biomedical Advanced Research and Development Authority

المصدر: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia

المؤلفون: Naoki Kotani, Michael Dolton, Robin J. Svensson, Jakob Ribbing, Lena E. Friberg, Shweta Vadhavkar, Dorothy Cheung, Tracy Staton, Gizette Sperinde, Jin Jin, Wendy S. Putnam, Angelica Quartino

المصدر: Journal of clinical pharmacology. 62(7)

مصطلحات موضوعية: Pharmacology, Body Weight, exposure-response, Antibodies, Monoclonal, asthma, ST2, Farmaceutiska vetenskaper, Antibodies, Monoclonal, Humanized, Asthma, Pharmaceutical Sciences, Clinical Trials, Phase II as Topic, population pharmacokinetics, IL-33, Humans, Pharmacology (medical), astegolimab

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e75333371eac26a2b3650a5271ad53d
https://pubmed.ncbi.nlm.nih.gov/34964491